These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31128856)

  • 1. The Swiss Hepatitis Strategy as a model for facing future health policy challenges.
    Blindenbacher R; Maeschli B; Bruggmann P
    Health Policy; 2019 Jul; 123(7):681-687. PubMed ID: 31128856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
    PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to set the agenda for hepatitis C: a theory-driven policy analysis.
    Kind J; Maeschli B; Bruggmann P
    Health Res Policy Syst; 2022 Feb; 20(1):20. PubMed ID: 35164777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How far is Mexico from Viral Hepatitis Global Health Sector Strategy 2030 targets.
    García-Sepúlveda CA; Laguna-Meraz S; Panduro A
    Ann Hepatol; 2020; 19(2):123-125. PubMed ID: 32138870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress, challenges and countermeasures of global hepatitis C elimination].
    Chen ZD
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):812-816. PubMed ID: 33105922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination.
    Lancaster K; Rhodes T; Rance J
    Int J Drug Policy; 2020 Jun; 80():102419. PubMed ID: 30975593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining the political influence of nurses who work in the field of hepatitis C: a Delphi survey.
    McKeown C; Gibson F
    J Clin Nurs; 2007 Jul; 16(7):1210-21. PubMed ID: 17584338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to treatment for hepatitis C virus infection: time to put patients first.
    Edlin BR
    Lancet Infect Dis; 2016 Sep; 16(9):e196-e201. PubMed ID: 27421993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradicating hepatitis C: The need for a public health response.
    Wallace J; Richmond J; Ellard J; Power J; Lucke J
    Glob Public Health; 2018 Sep; 13(9):1254-1264. PubMed ID: 30012072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus-related policy-making in Iran: a stakeholder and social network analysis.
    Behzadifar M; Gorji HA; Rezapour A; Rezvanian A; Bragazzi NL; Vatankhah S
    Health Res Policy Syst; 2019 Apr; 17(1):42. PubMed ID: 30992014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Political and Governance Challenges to Achieving Global HIV Goals with Injecting Drug Users: The Case of Pakistan.
    Khalid H; Fox AM
    Int J Health Policy Manag; 2019 May; 8(5):261-271. PubMed ID: 31204442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
    J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination.
    Brunner N; Bruggmann P
    J Prev Med Public Health; 2021 Jul; 54(4):251-258. PubMed ID: 34370938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliminating viral hepatitis C in Belgium: the micro-elimination approach.
    Busschots D; Toghanian S; Bielen R; Salomonsson S; Koc ÖM; Hendrickx G; Jadoul M; Nevens F; Sokal E; Brixko C; Peerlinck K; Apers L; Robaeys G; Lazarus JV
    BMC Infect Dis; 2020 Feb; 20(1):181. PubMed ID: 32106819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guidelines for the prevention and treatment of hepatitis C (2019 version)].
    ;
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):962-979. PubMed ID: 31941258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
    Lazarus JV; Stumo SR; Harris M; Hendrickx G; Hetherington KL; Maticic M; Jauffret-Roustide M; Tallada J; Simojoki K; Reic T; Safreed-Harmon K;
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25052. PubMed ID: 29633562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus prevention, care, and treatment: from policy to practice.
    Ward JW; Valdiserri RO; Koh HK
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S58-63. PubMed ID: 22715216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
    Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.